Intervacc progresses vaccine to prevent mastitis in dairy cows caused by Staphylococcus aureus
Stockholm, May 19, 2022 - Intervacc AB (publ) announces the initiation of a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by Staphylococcus aureus following successful safety and immunogenicity studies testing this prototype vaccine in pregnant heifers. This next phase of the project will be receiving a grant of 80k Euro from the EU’s VetBioNet initiative. Mastitis is one of the most important diseases of dairy cattle worldwide. Over 2.6 million cases of disease, causing losses of approximately 600M€, occur in European